SCHEMBL30795190

SCHEMBL30795190

CCSc1nc(N2CCOCC2)cc(C)c1C(=O)NCc1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.45
NAPEPLD Q6IQ20 1/20 0.43
PIK3CA P42336 4/20 0.42
PIK3CB P42338 4/20 0.42
PIK3CD O00329 3/20 0.42
PIK3CG P48736 2/20 0.42
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
CRHBP P24387 1/20 0.41
HTT P42858 1/20 0.41
CRHR2 Q13324 1/20 0.41
KLKB1 P03952 1/20 0.41
KLK1 P06870 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
AKT1 P31749 1/20 0.40
GBA1 P04062 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2130723 1.00 SRC (0.45) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2129031 0.97 SRC (0.44) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL30794521 0.97 SRC (0.44) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL19721583 0.95 SRC (0.42) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2711909 0.94 NAPEPLD (0.44) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2128514 0.94 SRC (0.45) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2130263 0.92 SRC (0.44) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL30794668 0.92 SRC (0.44) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2131351 0.92 SMN1; SMN2 (0.45) ALDH1A1LMNAHPGD
SCHEMBL30794366 0.92 SMN1; SMN2 (0.47) CRHBPCRHR2ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed